Waleed F. Khalil
Research Subjects
Waleed F. Khalil has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Elbeih
Military Technical College, Cairo, Egypt
1 shared publication Ahmed K. Hussein
1 shared publication- Ahmed Soliman Doghish
Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys) Al‐Azhar University Cairo Egypt
1 shared publication - Al-Aliaa M. Sallam
Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
1 shared publication - Gharieb S. El-Sayyad
Department of Biology, College of Science Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh Saudi Arabia
1 shared publication Mahmoud Abdelhafiz
1 shared publication
Latest Publications
- Open Access
- 1 September 2023
- Published by KEAI Publishing in Defence Technology
- Vol. 27, 1-8
An energetic nano-fiber composite based on polystyrene and 1,3,5-trinitro-1,3,5-triazinane fabricated via electrospinning technique
- 1 September 2023
- Published by KEAI Publishing in Defence Technology
- Vol. 27, 1-8
Open AccessAn energetic nano-fiber composite based on polystyrene and 1,3,5-trinitro-1,3,5-triazinane fabricated via electrospinning technique
- Open Access
- 23 August 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (46) , 29052-29064
Graphene oxide and its nanocomposites with EDTA or chitosan induce apoptosis in MCF-7 human breast cancer
To achieve the advanced anticancer activity of nanocomposites fabricated with graphene oxide (GO), a novel procedure was used during the fabrication of chitosan (CS) or ethylene diamine tetra acetic acid (EDTA). The synthesized GO-based nanocomposites were distinguished through different analytical techniques. The cytotoxic activity was examined using MTT assays against three different cancer cell lines. Cell cycle distribution and apoptosis were studied by flow cytometry. Caspase-8, caspase-9, and VEGFR-2 levels were determined using the ELISA technique. HRTEM results revealed a regular 2D thin sheet with a transparent surface in non-modified GO and for GO-CS, the surface of GO has clear cuts and lines had developed due to CS insertion. Concerning the MCF-7 breast cancer cell line, the lowest IC50 values were recorded, suggesting the most powerful cytotoxic effect on breast cancer cells. Treatment with GO-EDTA resulted in the lowest IC50 value of 3.8 ± 0.18 μg mL−1. As indicated by the annexin V-FITC apoptosis assay, the total apoptosis highest percentage was in GO-EDTA treatment (30.12%). In addition, the study of cell cycle analysis showed that GO-EDTA arrested the cell cycle primarily in the G0/G1 phase (33.74%). CS- and EDTA-conjugated GO showed an anti-cancer activity through their cytotoxic effect against the MCF-7 breast cancer cell line.
- 23 August 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (46) , 29052-29064
Open AccessGraphene oxide and its nanocomposites with EDTA or chitosan induce apoptosis in MCF-7 human breast cancer
To achieve the advanced anticancer activity of nanocomposites fabricated with graphene oxide (GO), a novel procedure was used during the fabrication of chitosan (CS) or ethylene diamine tetra acetic acid (EDTA). The synthesized GO-based nanocomposites were distinguished through different analytical techniques. The cytotoxic activity was examined using MTT assays against three different cancer cell lines. Cell cycle distribution and apoptosis were studied by flow cytometry. Caspase-8, caspase-9, and VEGFR-2 levels were determined using the ELISA technique. HRTEM results revealed a regular 2D thin sheet with a transparent surface in non-modified GO and for GO-CS, the surface of GO has clear cuts and lines had developed due to CS insertion. Concerning the MCF-7 breast cancer cell line, the lowest IC50 values were recorded, suggesting the most powerful cytotoxic effect on breast cancer cells. Treatment with GO-EDTA resulted in the lowest IC50 value of 3.8 ± 0.18 μg mL−1. As indicated by the annexin V-FITC apoptosis assay, the total apoptosis highest percentage was in GO-EDTA treatment (30.12%). In addition, the study of cell cycle analysis showed that GO-EDTA arrested the cell cycle primarily in the G0/G1 phase (33.74%). CS- and EDTA-conjugated GO showed an anti-cancer activity through their cytotoxic effect against the MCF-7 breast cancer cell line.